Physician profile
Peter Scudera
NPI 1063488575
$2,759.92
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $980 · 2020: $491 · 2021: $1,273 · 2022: $16.36.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $875.41 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $439.03 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $283.11 | 2019-2021 | |
| Gilead Sciences, INC. | $228.80 | 2019-2021 | |
| Qol Medical, LLC | $170.80 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $115.18 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $108.80 | 2019-2021 | |
| Pfizer INC. | $91.24 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $84.39 | 2019-2022 | |
| Shionogi INC | $82.34 | 2019-2020 | |
| Celgene Corporation | $70.96 | 2021 | |
| Janssen Biotech, INC. | $60.36 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $37.92 | 2019 | |
| Romark Laboratories, Lc | $29.00 | 2020 | |
| Nestle Healthcare Nutrition INC. | $27.39 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $24.34 | 2020 | |
| Alfasigma USA, INC. | $15.83 | 2020 | |
| Braintree Laboratories, INC. | $15.02 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Scudera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.